The possibility of treating patients who cannot tolerate statins has long been eyed as a valuable segment of the cholesterol market, but has been a difficult claim to get past regulators. However, recent developments arguably may help build a market for what has been a hard-to-define population.
The majority of the cholesterol market is well-served by statins, which offer effective LDL lowering now as oral generic drugs....







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
